Keyphrases
Locally Advanced
100%
Locally Advanced Esophageal Carcinoma
100%
Immune Checkpoint Inhibitors
100%
Disease-free Survival
66%
Gastroesophageal Junction Cancer
66%
Standard of Care
66%
Neoadjuvant Setting
66%
Neoadjuvant Chemoradiotherapy (nCRT)
66%
Perioperative Immunotherapy
66%
Surgical Resection
33%
Adjuvant Therapy
33%
Adenocarcinoma
33%
Ongoing Trials
33%
Complete Response Rate
33%
Phase II Trial
33%
Chemoradiotherapy
33%
Response Rate
33%
Clinical Trials
33%
Preoperative Chemotherapy
33%
Esophageal Carcinoma
33%
Pathological Complete Response
33%
Esophageal Squamous Cell Carcinoma
33%
Early Phase Clinical Trials
33%
Safety Profile
33%
Neoadjuvant
33%
Literature Search
33%
Surgical Morbidity
33%
Historical Controls
33%
Advanced Esophageal Cancer
33%
PubMed
33%
Residual Disease
33%
Mismatch Repair
33%
Surgical Mortality
33%
Adverse Event Rates
33%
Multimodality Approach
33%
Perioperative Setting
33%
R0 Resection Rate
33%
Gastroesophageal Junction Carcinoma
33%
Practice Changing
33%
Online Database
33%
Neoadjuvant Immunotherapy
33%
Nivolumab
33%
Dual Checkpoint Inhibition
33%
Medicine and Dentistry
Immunotherapy
100%
Esophagus Carcinoma
100%
Chemoradiotherapy
42%
Gastroesophageal Junction
42%
Immune Checkpoint Inhibitor
42%
Cancer
28%
Disease Free Survival
28%
Surgery
28%
Adjuvant Therapy
14%
Adenocarcinoma
14%
Esophageal Cancer
14%
Adverse Event
14%
Carcinoma
14%
Minimal Residual Disease
14%
Esophageal Squamous Cell Carcinoma
14%
DNA Mismatch Repair
14%
Immunotherapy Clinical Trial
14%
Nivolumab
14%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Esophagus Carcinoma
100%
Chemoradiation Therapy
42%
Immune Checkpoint Inhibitor
42%
Disease Free Survival
28%
Esophagus Cancer
14%
Chemotherapy
14%
Adenocarcinoma
14%
Adverse Event
14%
Carcinoma
14%
Esophageal Squamous Cell Carcinoma
14%
Minimal Residual Disease
14%
Immunotherapy Clinical Trial
14%
Nivolumab
14%